Showing Form 4 filings for DFTX
Pre-configured institutional-grade criteria for instant high-conviction screening
Multiple insiders buying stock within the last 30 days
Direct open-market purchases by Chief Executive Officers
Financial chiefs and top corporate officers accumulating shares
Institutional-scale insider purchases of $1,000,000 or greater
Insiders increasing their overall equity ownership by over 20%
High-value executive divestments by CEOs and CFOs over $1M
Definium Therapeutics, Inc.
Price
$36.57
Shares
10,853
Ownership
792,846
Value/Share
Karlin Daniel
Chief Medical Officer
Industry
31,550
2,213,090
Barrow Robert
CEO
3,097
359,036
Wiley Matthew T.
Chief Commercial Officer
14,051
494,228
Sullivan Mark
GC
3,377
394,528
Roberts Brandi
CFO